ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 187,65
0,69%
Dow Jones
39 387,76
0,85%
DAX
18 686,60
1,07%
Brent Oil
83,955
0,47%
Bitcoin
62 535,41
2,20%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Arcutis Biotherapeutics Inc (ARQT)

  7. Arcutis Biotherapeutics Inc (ARQT) Actualités

ARQT

Arcutis Biotherapeutics (ARQT)

Arcutis Biotherapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ARQT
DateHeureSourceTitreSymboleSociété
03/05/202422h00GlobeNewswire Inc.Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ARQTArcutis Biotherapeutics Inc
29/04/202422h00GlobeNewswire Inc.Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024NASDAQ:ARQTArcutis Biotherapeutics Inc
10/04/202414h00GlobeNewswire Inc.Arcutis Appoints David Topper as Chief Financial OfficerNASDAQ:ARQTArcutis Biotherapeutics Inc
01/04/202413h00GlobeNewswire Inc.Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® CreamNASDAQ:ARQTArcutis Biotherapeutics Inc
28/03/202413h00GlobeNewswire Inc.Arcutis to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:ARQTArcutis Biotherapeutics Inc
11/03/202413h00GlobeNewswire Inc.Arcutis Promotes Todd Tucker to Chief Human Resources OfficerNASDAQ:ARQTArcutis Biotherapeutics Inc
10/03/202421h00GlobeNewswire Inc.Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual MeetingNASDAQ:ARQTArcutis Biotherapeutics Inc
09/03/202422h00GlobeNewswire Inc.New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier DysfunctionNASDAQ:ARQTArcutis Biotherapeutics Inc
06/03/202423h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
04/03/202423h47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
04/03/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARQTArcutis Biotherapeutics Inc
04/03/202422h00GlobeNewswire Inc.Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesNASDAQ:ARQTArcutis Biotherapeutics Inc
04/03/202414h00GlobeNewswire Inc.Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual MeetingNASDAQ:ARQTArcutis Biotherapeutics Inc
01/03/202422h06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARQTArcutis Biotherapeutics Inc
29/02/202423h00GlobeNewswire Inc.Arcutis to Present at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:ARQTArcutis Biotherapeutics Inc
29/02/202405h30GlobeNewswire Inc.Arcutis Announces Pricing of $150 Million Public OfferingNASDAQ:ARQTArcutis Biotherapeutics Inc
28/02/202422h10GlobeNewswire Inc.Arcutis Announces Proposed Public OfferingNASDAQ:ARQTArcutis Biotherapeutics Inc
28/02/202422h00GlobeNewswire Inc.Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in JapanNASDAQ:ARQTArcutis Biotherapeutics Inc
27/02/202422h34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ARQTArcutis Biotherapeutics Inc
27/02/202413h48Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ARQTArcutis Biotherapeutics Inc
27/02/202411h50GlobeNewswire Inc.Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:ARQTArcutis Biotherapeutics Inc
16/02/202414h00GlobeNewswire Inc.Arcutis to Report Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ARQTArcutis Biotherapeutics Inc
15/02/202422h19Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:ARQTArcutis Biotherapeutics Inc
13/02/202415h26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ARQTArcutis Biotherapeutics Inc
09/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ARQTArcutis Biotherapeutics Inc
31/01/202423h22Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ARQTArcutis Biotherapeutics Inc
31/01/202414h00GlobeNewswire Inc.Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology ConferenceNASDAQ:ARQTArcutis Biotherapeutics Inc
29/01/202414h00GlobeNewswire Inc.Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 TrialNASDAQ:ARQTArcutis Biotherapeutics Inc
22/01/202414h00GlobeNewswire Inc.ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United StatesNASDAQ:ARQTArcutis Biotherapeutics Inc
14/01/202410h00GlobeNewswire Inc.ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical SteroidsNASDAQ:ARQTArcutis Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ARQT

Dernières Valeurs Consultées

COIN
BTCUSD
Bitcoin
EU
BEL20
Bel 20
NASDAQ
GOOGL
Alphabet
EU
MC
Lvmh Moet Hennessy Louis...
EU
RNO
Renault
COIN
ETHUSD
Ethereum
EU
RI
Pernod Ricard
NASDAQ
AAPL
Apple
EU
ACA
Credit Agricole
NYSE
KO
Coca Cola
NYSE
MCD
McDonalds
EU
CAP
Capgemini
EU
VK
Vallourec
NYSE
JPM
JP Morgan Chase
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés